Reuters logo
BRIEF-Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln
October 25, 2017 / 8:19 PM / a month ago

BRIEF-Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln

Oct 25 (Reuters) - Sarepta Therapeutics Inc:

* Sarepta Therapeutics announces third quarter 2017 financial results and recent corporate developments

* Q3 non-GAAP loss per share $0.20

* Q3 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S

* Q3 GAAP loss per share $0.78

* Sees FY 2017 revenue $150 million to $155 million

* Q3 revenue $46 million versus I/B/E/S view $40.8 million

* Sarepta Therapeutics Inc - ‍raises annual 2017 revenue guidance to between $150 million and $155 million​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below